Showing results (41-50 of 227) with videos related to
Sort By:
Pageof 23
British Journal of Haematology|February 8, 2020
Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapyStephen D Smith, Brian G Till, Mazyar S Shadman, et al.Journal of Cellular and Molecular Medicine|December 1, 2022
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world studyLorenzo Iovino, Qian Vicky Wu, Jenna Voutsinas, et al.Leukemia & Lymphoma|July 11, 2022
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphomaLorena Panaite, Qian Vicky Wu, Jenna Voutsinas, et al.Blood Advances|November 17, 2022
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHLSolomon A Graf, Ryan C Lynch, Chaitra S Ujjani, et al.Clinical Lymphoma, Myeloma & Leukemia|November 5, 2023
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-UpCarrie Ho, Ajay K Gopal, Brian G Till, et al.Clinical Lymphoma, Myeloma & Leukemia|April 6, 2019
Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution ExperienceJason P Cooper, Sirin Khajaviyan, Stephen D Smith, et al.Blood|April 1, 2009
131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphomaAjay K Gopal, John M Pagel, Jonathan R Fromm, et al.Cancer Genetics|March 23, 2024
Assessment for 11q and other chromosomal aberrations in large B-cell/high-grade B cell lymphomas of germinal center phenotype lacking BCL2 expressionChia-Chen Ho, Kikkeri Naresh, Yajuan Liu, et al.Clinical Lymphoma, Myeloma & Leukemia|January 6, 2026
HIV, HBV, and HCV Testing in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Experience From a Comprehensive Cancer CenterC Natasha Kwendakwema, Kristine F Lan, H Nina Kim, et al.Blood|May 27, 2008
Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 AbAjay K Gopal, Oliver W Press, Shani M Wilbur, et al.Pageof 23